Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tivozanib in Advanced Inoperable Hepatocellular Carcinoma
NCT01835223Phase 2Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Jul 2013
- Primary completion
- Dec 2018
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of tivozanib in hepatocellular carcinoma (HCC), sponsored by Roswell Park Comprehensive Cancer Center. Started Jul 2013; status: completed.
02
Drugs
tivozanib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01835223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01835223.